Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of VDJ-002 (CTLA-4-Fc) in Healthy Subjects
NCT05256719Phase 1Recruiting
- Sponsor
- Beijing VDJBio Co., Ltd.
- Start
- Sep 2021
- Primary completion
- Dec 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VDJ-002 in autoimmune diseases, sponsored by Beijing VDJBio Co., Ltd. Primary endpoint: Number of subjects with adverse events at Day 85. Started Sep 2021; status: recruiting.
02
Drugs
VDJ-002
03
Conditions
autoimmune diseases
Beyond the preview
Go deeper on NCT05256719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05256719.